Switch theme
Sign up to access all valuation multiples
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
2000
95
LTM Revenue $3.4M
Last FY EBITDA -$52.8M
$240M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ocugen has a last 12-month revenue (LTM) of $3.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ocugen achieved revenue of $4.1M and an EBITDA of -$52.8M.
Ocugen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ocugen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4M | XXX | $4.1M | XXX | XXX | XXX |
| Gross Profit | $3.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$52.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1302% | XXX | XXX | XXX |
| EBIT | -$57.7M | XXX | -$54.8M | XXX | XXX | XXX |
| EBIT Margin | -1686% | XXX | -1350% | XXX | XXX | XXX |
| Net Profit | -$58.1M | XXX | -$54.1M | XXX | XXX | XXX |
| Net Margin | -1699% | XXX | -1333% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ocugen's stock price is $1.
Ocugen has current market cap of $246M, and EV of $240M.
See Ocugen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $246M | XXX | XXX | XXX | XXX | $-0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ocugen has market cap of $246M and EV of $240M.
Ocugen's trades at 59.2x EV/Revenue multiple, and -4.6x EV/EBITDA.
Equity research analysts estimate Ocugen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ocugen has a P/E ratio of -4.2x.
See valuation multiples for Ocugen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $246M | XXX | $246M | XXX | XXX | XXX |
| EV (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV/Revenue | 70.2x | XXX | 59.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.6x | XXX | XXX | XXX |
| EV/EBIT | -4.2x | XXX | -4.4x | XXX | XXX | XXX |
| EV/Gross Profit | 70.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.2x | XXX | -4.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOcugen's last 12 month revenue growth is -31%
Ocugen's revenue per employee in the last FY averaged $43K, while opex per employee averaged $0.6M for the same period.
Ocugen's rule of 40 is -1105% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ocugen's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ocugen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -31% | XXX | -27% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1302% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1105% | XXX | -1332% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 792% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1450% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ocugen acquired XXX companies to date.
Last acquisition by Ocugen was XXXXXXXX, XXXXX XXXXX XXXXXX . Ocugen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ocugen founded? | Ocugen was founded in 2000. |
| Where is Ocugen headquartered? | Ocugen is headquartered in United States of America. |
| How many employees does Ocugen have? | As of today, Ocugen has 95 employees. |
| Who is the CEO of Ocugen? | Ocugen's CEO is Dr. Shankar Musunuri, M.B.A.,PhD. |
| Is Ocugen publicy listed? | Yes, Ocugen is a public company listed on NAS. |
| What is the stock symbol of Ocugen? | Ocugen trades under OCGN ticker. |
| When did Ocugen go public? | Ocugen went public in 2014. |
| Who are competitors of Ocugen? | Similar companies to Ocugen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ocugen? | Ocugen's current market cap is $246M |
| What is the current revenue of Ocugen? | Ocugen's last 12 months revenue is $3.4M. |
| What is the current revenue growth of Ocugen? | Ocugen revenue growth (NTM/LTM) is -31%. |
| What is the current EV/Revenue multiple of Ocugen? | Current revenue multiple of Ocugen is 70.2x. |
| Is Ocugen profitable? | Yes, Ocugen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
